Crossmark

Spanish National Hip Fracture Registry (RNFC): analysis of its first annual report and international comparison with other established registries

Crossref DOI link: https://doi.org/10.1007/s00198-019-04939-2

Published Online: 2019-03-23

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Ojeda-Thies, C. https://orcid.org/0000-0001-7052-1491
Sáez-López, P.

Currie, C.T.

Tarazona-Santalbina, F.J.

Alarcón, T.

Muñoz-Pascual, A.

Pareja, T.

Gómez-Campelo, P.

Montero-Fernández, N.

Mora-Fernández, J.

Larrainzar-Garijo, R.

Gil-Garay, E.

Etxebarría-Foronda, I.

Caeiro, J.R.

Díez-Pérez, A.

Prieto-Alhambra, D.

Navarro-Castellanos, L.

Otero-Puime, A.

González-Montalvo, J.I.
Funding

Funding for this research was provided by:

Fundación Mutua Madrileña (AP169672018)

Amgen

UCB UK
License Information

Text and Data Mining valid from 2019-03-23
More Information

Article History

Received: 7 January 2019

Accepted: 11 March 2019

First Online: 23 March 2019

Compliance with ethical standards

:

: The following authors have no conflicts of interest to declare: Currie CT5, Alarcón T2,8, Gómez-Campelo P2,11, Gil-Garay E2,8, Larrainzar-Garijo R15, Navarro-Castellanos L2, Otero-Puime A2,21.The following authors declare:Ojeda-Thies C1 has received honoraria for speaking at symposia from Amgen and financial support for attending symposia from Amgen and UCB Pharma; none of them related with the present work.Sáez López P2,3,4 has received honoraria for speaking at symposia and financial support for attending symposia from Abbott, Nestlé and Amgen, none of them related with the present work.Tarazona-Santalbina FJ6,7 has received honoraria for speaking at symposia and financial support for attending symposia from Lilly, Abbott, and Amgen; none of them related with the present work.Muñoz-Pascual A9 has received financial support for attending symposia from Nutricia laboratories; none of them related with the present work.Pareja T10 has received honoraria for speaking at symposia from Abbott and financial support for attending symposia from AMGEN and Vifor Pharma; none of them related with the present work.Montero-Fernández N12,13 has received honoraria for speaking at symposia from Abbott, and financial support for attending symposia and educational programs from Abbott, Amgen, and Eli-Lilly; none of them related with the present work.Mora-Fernández J14 has received honoraria for speaking at symposia, financial support for attending symposia, and support as a project sponsor from Amgen, Lilly, and UCB Pharma; none of them related with the present work.Etxebarría-Foronda I16 has received honoraria for peaking at symposia from Eli-Lilly; none of them related with the present work.Caeiro JR17 has received financial support for attending symposia and support for educational programs of Amgen, Lilly, Stryker, and Zimmer Companies; none of them related with the present work.Díez-Pérez A18 is advisor of has received speaker honoraria from AMGEN, UCB, Lilly, Gilead, Roche, and EchoLight and owns stocks from Active Life Sci; none of them related with the present work.Prieto-Alhambra D’s19,20 research group has received grants from UCB, and speaker fees (paid to his department) from Amgen and UCB, and consultancy fees (paid to his department) from Amgen, Janssen, and UCB; none of them related with the present work.González-Montalvo JI2,8 has received research grants from Nestlé Health Science and Abbott Nutrition; has received speaker honoraria from Nutricia, Nestlé Health Science, Amgen, and Abbott Nutrition; and has received financial support for educational programs from Nutricia and Amgen. None of them related with the present work.

Document is current

Any future updates will be listed below